semaglutidesurvodutidetirzepatide
…, whereby researchers are investigating the use of subcutaneous semaglutide 2.4 mg/week for the treatment of adults with non-cirrhotic MASH…
9articles mentioning drugs
46drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: resmetirom ×
resmetirom
This drug is selected. Its supporting articles are shown below.
Articles mentioning resmetirom
9 articles · page 1 of 1resmetiromPDFFMASLDcirrhosisF2-F3 metabolic dysfunction- associated steatohepatitis
… decreases were observed in non-cirrhotic patients treated with resmetirom. In addition, non-cirrhotic patients receiving resmetirom exper…
ResmetiromMASHmetabolic dysfunction-associated steatohepatitisNASHCSPHMASH cirrhosis
…g and portal hypertension risk in patients with MASH cirrhosis. Resmetirom was safe and well-tolerated in this population. These findings …
metforminpioglitazonesemaglutideresmetiromMig-6insulinsulfonylureas
…2.67, 71 subjects were on oral hypoglycemic medications such as metformin, sulfonylureas, pioglitazone, DPP-4 inhibitors, and SGLT2 inhib…
resmetiromglucagon-like peptide-1 receptor agonistslifestyle modificationMetabolic dysfunction-associated steatotic liver disease (MASLD)
…prevent malnutrition in elderly adults. Novel therapies such as resmetirom and glucagon-like peptide-1 receptor agonists show promising ef…
semaglutideresmetiromQF70hepatocellular carcinomacirrhosisFDAUS food and drug administrationmetabolic dysfunction-associated steatotic liver disease (MASLD)
…d-stage liver diseases. However, only two drugs, resmetirom and semaglutide, have been approved by the US food and drug administration (FDA…
semaglutide1 2resmetiromhepatocellular carcinomatype 2 diabetesMetabolic dysfunction-associated steatotic liver diseaseMASHmetabolic dysfunction-associated steatohepatitiscirrhosisliver failurenovel pharmacological therapies+1 more
…hepatocellular carcinoma. The recent approval of resmetirom and semaglutide1 2 for active, fibrotic MASH (F2–F3) highlights the urgent need fo…
resmetiromNASH cirrhosisNCT05500222Gilbert’s syndrome
…is. Patients were randomized 3:1 in a blinded manner to receive resmetirom 80 mg or matching placebo given orally once daily in the mornin…
resmetiromUS Food and Drug Administrationmetabolic dysfunction-associated steatotic liver disease (MASLD)F2/F3 liver fibrosis
…With the recent conditional approval of resmetirom by the US Food and Drug Administration, the treatment of metabo…